RANI Company Profile and Key Details

Q: Who are the executives of RANI?

Mr. Mir A. ImranExecutive ChairmanMr. Svai S. SanfordChief Financial OfficerMr. Talat ImranChief Executive Officer & DirectorDr. Mir HashimChief Scientific OfficerMr. Eric GroenGen. CounselMs. Bella VazquezVice President of HRMs. Kate McKinley M.B.A.Chief Bus. Officer

NASDAQ : RANI

Rani Therapeutics

$0.77

-0.0097-1.24%

At Close 4:00 PM

61.08

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Rani Therapeutics Holdings, Inc. (RANI) stock declined over -1.24%, trading at $0.77 on NASDAQ, down from the previous close of $0.78. The stock opened at $0.78, fluctuating between $0.77 and $0.83 in the recent session.

Stock Snapshot

0.7824

Prev. Close

50.47M

Market Cap

0.7704

Day Low

-2.86

P/E Ratio

-0.27

EPS (TTM)

-2.03

Cash Flow per Share

0.78

Open

65.32M

Number of Shares

0.8298

Day High

72.16%

Free Float in %

0.5

Book Value

604.02K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	0.78	0.83	0.77	0.77	609.24K
Jun 18, 2026	0.77	0.79	0.77	0.78	303.04K
Jun 17, 2026	0.75	0.80	0.75	0.77	556.3K
Jun 16, 2026	0.76	0.78	0.73	0.76	749.99K
Jun 15, 2026	0.80	0.81	0.76	0.77	792.77K
Jun 12, 2026	0.79	0.81	0.76	0.76	897.12K
Jun 11, 2026	0.80	0.81	0.76	0.80	551.42K
Jun 10, 2026	0.82	0.83	0.77	0.78	557.95K
Jun 09, 2026	0.84	0.85	0.80	0.81	1.19M
Jun 08, 2026	0.84	0.85	0.82	0.84	486.44K
Jun 05, 2026	0.89	0.90	0.81	0.83	845.34K
Jun 04, 2026	0.86	0.93	0.86	0.90	707.19K
Jun 03, 2026	0.86	0.88	0.83	0.88	707.59K
Jun 01, 2026	0.95	0.96	0.89	0.90	2.04M
May 29, 2026	0.95	0.99	0.93	0.95	1M
May 28, 2026	0.93	0.99	0.92	0.95	1.09M
May 27, 2026	0.92	0.96	0.92	0.95	804.66K
May 26, 2026	0.99	0.99	0.92	0.94	1.94M
May 22, 2026	1.07	1.10	1.05	1.07	726.23K
May 21, 2026	1.06	1.11	1.05	1.07	1M

Contact Details

San Jose, CA 95131

United States

https://www.ranitherapeutics.com 408 457 3700

About Company

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) closed at $0.77 USD, losing -$0.01 (-1.24%) from the previous close of $0.78. The stock is currently mid-range between its 52-week high and low $0.39 and $3.87. With a market capitalization of about $50.47 million, Rani Therapeutics Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.76). Key stats such as the average daily volume over the past year has been around 1.09 million shares, volume is running light vs its 52-week average. Headquartered in San Jose, CA, Rani Therapeutics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Talat Imran, the company employs approximately 105 people and listed since July 30, 2021. Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 8.92%, SMA50 2.13%, SMA200 38.3%). The stock’s 14-day RSI is 56.7 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -64.34% below its high and over 256.59% above its low. Average 10-day trading volume of 602.27 thousand shares is below the 3-month average of 1.07 million, indicating normal recent market interest.

Valuation Metrics

Rani Therapeutics Holdings, Inc. trades at a P/E ratio of -1.95, slightly below the S&P 500 average, with a price-to-sales ratio of 16.41 and a price-to-book ratio of 5.04 trading at moderately above to book value. The P/FCF stands at -3.04, also above market averages.

Dividend & Fair Value

Rani Therapeutics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.16. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Rani Therapeutics Holdings, Inc. generated EPS of -$0.79 over the past year. Five-year average earnings growth is 4.78%. Wall Street analysts project EPS growth of 35.44% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.05. Next year's EPS is expected at $22.51. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $5.00. The high target offers 1328.57% upside. The low target suggests 549.35% downside. The mean target is $8.83. This offers 1046.75% upside. Rani Therapeutics Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by -42.86%. The prior quarter beat by 133.33%. Over the last six quarters, Apple has recorded several small beats. These include 12.5% in March 31, 2025.

Shareholding & Insider Activity

Rani Therapeutics Holdings, Inc. has 47.90 million shares outstanding. The public float is 33.62 million shares, elevated short interest at 0.27% of float. This equals 103.47 thousand shares. The short ratio is 0.15 days. Institutional investors hold 46.19% of the float. Insiders own 5.01%. Quiroga Moreno Isidoro holds 8.16 million shares, South Cone Investments Limited Partnership has 2.38 million shares and IMRAN MIR A has 2.08 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Rani Therapeutics has not generated any revenue. Returns are negative, with ROA at -58.65% and ROE at -264.03%.
On valuation metrics, Rani Therapeutics trades at a P/E of -1.95, P/S of 16.41 and P/B of 5.04. The current ratio is 3.40 and quick ratio is 3.40. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1701.78 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.14, supported by a cash flow-to-debt ratio of -4.33.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Rani Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $822.00K (margin 0.00%). Operating income was - $66.10M (margin 0.0%). Net income was- $33.97M (EPS - $1.33).
The company ended the quarter with $49.04M in cash and short-term investments, a total debt of $30.10M, and net debt of $23.74M. Total assets were $57.92M, with equity of $25.44M. Financials further reflected weakness, with operating cash flow of - $51.24M, free cash flow of - $52.47M, and capital expenditures of - $1.23M.

Price Forecast & Outlook

Our AI price prediction model suggests that Rani Therapeutics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.88%, with price expected at $0.65 by July 06, 2026, within a range of $0.59 to $0.71 3-Month Outlook: Projected fall of -80.59%, reaching $0.15 by September 16, 2026, with a range of $0.06 to $0.19. 1-Year Outlook: Projected gain of 37.18%, with price at $1.06 by June 22, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares are flat 0.74% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Rani Therapeutics Holdings, Inc. trading at a premium to the broader market with a P/E of -1.95. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.90, suggesting 1828.3% upside. Our AI forecast model points to short-term weakness (-15.88% over two weeks), a medium-term fall (-80.59% over three months), and a longer-term gain (37.18% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Rani Therapeutics Holdings, Inc. (RANI) stock price?

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) stock price is $0.77 in the last trading session. During the trading session, RANI stock reached the peak price of $0.83 while $0.77 was the lowest point it dropped to. The percentage change in RANI stock occurred in the recent session was -1.24% while the dollar amount for the price change in RANI stock was - $0.01.

RANI's industry and sector of operation?

The NASDAQ listed RANI is part of Biotechnology industry that operates in the broader Healthcare sector. Rani Therapeutics Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RANI?

Mr. Mir A. Imran
Executive Chairman
Mr. Svai S. Sanford
Chief Financial Officer
Mr. Talat Imran
Chief Executive Officer & Director
Dr. Mir Hashim
Chief Scientific Officer
Mr. Eric Groen
Gen. Counsel
Ms. Bella Vazquez
Vice President of HR
Ms. Kate McKinley M.B.A.
Chief Bus. Officer

How RANI did perform over past 52-week?

RANI's closing price is 99.66% higher than its 52-week low of $0.39 where as its distance from 52-week high of $3.87 is -80.03%.

How many employees does RANI have?

Number of RANI employees currently stands at 105.

Link for RANI official website?

Official Website of RANI is: https://www.ranitherapeutics.com

How do I contact RANI?

RANI could be contacted at phone 408 457 3700 and can also be accessed through its website. RANI operates from 2051 Ringwood Avenue, San Jose, CA 95131, United States.

How many shares of RANI are traded daily?

RANI stock volume for the day was 604.02K shares. The average number of RANI shares traded daily for last 3 months was 1.09M.

What is the market cap of RANI currently?

The market value of RANI currently stands at $50.47M with its latest stock price at $0.77 and 65.32M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	105
Beta	0.76
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RANI Company Profile and Key Details

Rani Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics